Journal of Biological Chemistry · 2000 · 58 citations · 39 references
MedicineMolecular BiologyOncologyCancer GeneticsGene ExpressionMolecular OncologyCancer MetabolismCytotoxic ChemotherapyNucleoside AnalogsPyrimidine AnalogsRetroviral Vector Transduction
Nucleoside kinases from several species are investigated as “suicide genes” for treatment of malignant tumors by combined gene/chemotherapy. We have recently cloned a multisubstrate deoxyribonucleoside kinase of Drosophila melanogaster(Dm-dNK), and we have shown that the enzyme phosphorylates cytotoxic pyrimidine and purine nucleoside analogs. The broad substrate specificity of the enzyme, as well as its very high catalytic rate, makes it a unique member of the nucleoside kinase enzyme family. In the present study, we evaluated Dm-dNK as a suicide gene by constructing a replication-deficient retroviral vector that expresses the enzyme. The human pancreatic adenocarcinoma cell line MIA PaCa-2 and a thymidine kinase-deficient osteosarcoma cell line were transduced with the recombinant virus. We showed that Dm-dNK can be expressed in human cells, that the enzyme retained its enzymatic activity, and that it is localized in the cell nuclei due to a nuclear localization signal in its C-terminal region. The cells expressingDm-dNK exhibited increased sensitivity to several cytotoxic nucleoside analogs, such as 1-β-d-arabinofuranosylcytosine, 1-β-d-arabinofuranosylthymine, (E)-5-(2-bromovinyl)-2′-deoxyuridine, 2-chloro-2′-deoxyadenosine, and 2′,2′-difluorodeoxycytidine. These findings suggest that Dm-dNK may be used as a suicide gene in combined gene/chemotherapy of cancer. Nucleoside kinases from several species are investigated as “suicide genes” for treatment of malignant tumors by combined gene/chemotherapy. We have recently cloned a multisubstrate deoxyribonucleoside kinase of Drosophila melanogaster(Dm-dNK), and we have shown that the enzyme phosphorylates cytotoxic pyrimidine and purine nucleoside analogs. The broad substrate specificity of the enzyme, as well as its very high catalytic rate, makes it a unique member of the nucleoside kinase enzyme family. In the present study, we evaluated Dm-dNK as a suicide gene by constructing a replication-deficient retroviral vector that expresses the enzyme. The human pancreatic adenocarcinoma cell line MIA PaCa-2 and a thymidine kinase-deficient osteosarcoma cell line were transduced with the recombinant virus. We showed that Dm-dNK can be expressed in human cells, that the enzyme retained its enzymatic activity, and that it is localized in the cell nuclei due to a nuclear localization signal in its C-terminal region. The cells expressingDm-dNK exhibited increased sensitivity to several cytotoxic nucleoside analogs, such as 1-β-d-arabinofuranosylcytosine, 1-β-d-arabinofuranosylthymine, (E)-5-(2-bromovinyl)-2′-deoxyuridine, 2-chloro-2′-deoxyadenosine, and 2′,2′-difluorodeoxycytidine. These findings suggest that Dm-dNK may be used as a suicide gene in combined gene/chemotherapy of cancer. herpes simplex virus type-1 thymidine kinase 9-β-d-arabinofuranosyladenine 1-β-d-arabinofuranosylcytosine 9-β-d-arabinofuranosylguanine 1-β-d-arabinofuranosylthymine (E)-5-(2-bromovinyl)-2′-deoxyuridine 2-chloro-2′-deoxyadenosine 4′,6′-diamidino-2-phenylindole 2′,2′-difluorodeoxycytidine Drosophila melanogaster deoxyribonucleoside kinase green fluorescent protein The transfer of the gene encoding herpes simplex virus type-1 thymidine kinase (HSV-1 TK)1into malignant cells and subsequent treatment with ganciclovir is one of the most commonly studied strategies of suicide gene therapy (1Moolten F.L. Cancer Res. 1986; 46: 5276-5281PubMed Google Scholar, 2Moolten F.L. Wells J.M. J. Natl. Cancer Inst. 1990; 82: 297-300Crossref PubMed Scopus (500) Google Scholar, 3Culver K.W. Ram Z. Wallbridge S. Ishii H. Oldfield E.H. Blaese R.M. Science. 1992; 256: 1550-1552Crossref PubMed Scopus (1459) Google Scholar, 4Ram Z. Culver K.W. Oshiro E.M. Viola J.J. DeVroom H.L. Otto E. Long Z. Chiang Y. McGarrity G.J. Muul L.M. Katz D. Blaese R.M. Oldfield E.H. Nat. Med. 1997; 3: 1354-1361Crossref PubMed Scopus (641) Google Scholar, 5Klatzmann D. Valéry C.A. Bensimon G. Marro B. Boyer O. Mokhtari K. Diquet B. Salzmann J.-L. Philippon J. the Study Group on Gene Therapy for Glioblastoma Hum. Gene Ther. 1998; 9: 2595-2604Crossref PubMed Google Scholar). The HSV-1 TK gene is introduced into cancer cells using either viral or non-viral vectors. The nucleoside kinase phosphorylates nucleoside analogs such as the guanosine analog ganciclovir to their monophosphate derivatives, and cellular enzymes further phosphorylate the compounds to their triphosphate forms. Ganciclovir triphosphate interferes with DNA replication (6Reardon J.E. J. Biol. Chem. 1989; 264: 19039-19044Abstract Full Text PDF PubMed Google Scholar) and induces cell death, probably by apoptosis (7Freeman S.M. Abboud C.N. Whartenby K.A. Packman C.H. Koeplin D.S. Moolten F.L. Abraham G.N. Cancer Res. 1993; 53: 5274-5283PubMed Google Scholar, 8Beltinger C. Fulda S. Kammertoens T. Meyer E. Uckert W. Debatin K.-M. Proc. Natl. Acad. Sci. U. S. A. 1999; 96: 8699-8704Crossref PubMed Scopus (154) Google Scholar). In addition to affecting the cells expressing HSV-1 TK, adjacent untransduced cancer cells are killed by the transfer of phosphorylated nucleoside analog between cells via gap junctions (7Freeman S.M. Abboud C.N. Whartenby K.A. Packman C.H. Koeplin D.S. Moolten F.L. Abraham G.N. Cancer Res. 1993; 53: 5274-5283PubMed Google Scholar, 9Mesnil M. Piccoli C. Tiraby G. Willecke K. Yamasaki H. Proc. Natl. Acad. Sci. U. S. A. 1996; 93: 1831-1835Crossref PubMed Scopus (401) Google Scholar). This phenomenon, known as the “bystander effect,” results in killing of a larger portion of cells than those transduced with the suicide gene. One limiting factor for the efficiency of suicide gene therapy is the kinetic properties of the “suicide” nucleoside kinase. Genetically engineered mutants of HSV-1 TK with improved kinetic properties for nucleoside analog phosphorylation show increased efficiencies as suicide genes (10Black M.E. Newcomb T.G. Wilson H.-M.P. Loeb L.A. Proc. Natl. Acad. Sci. U. S. A. 1996; 93: 3525-3529Crossref PubMed Scopus (262) Google Scholar, 11Christians F.C. Scapozza L. Crameri A. Folkers G. Stemmer W.P.C. Nat. Biotechnol. 1999; 17: 259-264Crossref PubMed Scopus (114) Google Scholar, 12Kokoris M.S. Sabo P. Adman E.T. Black M.E. Gene Ther. 1999; 6: 1415-1426Crossref PubMed Scopus (80) Google Scholar). Nucleoside kinases from different members of the herpesvirus family, such as herpes simplex virus type 2 and varicella zoster virus, have also been studied for possible use as suicide genes (13Balzarini J. Bohman C. De Clercq E. J. Biol. Chem. 1993; 268: 6332-6337Abstract Full Text PDF PubMed Google Scholar, 14Degrève B. Andrei G. Izquierdo M. Piette J. Morin K. Knaus E.E. Wiebe L.I. Basrah I. Walker R.T. De Clercq E. Balzarini J. Gene Ther. 1997; 4: 1107-1114Crossref PubMed Scopus (46) Google Scholar, 15Grignet-Debrus C. Calberg-Bacq C.-M. Gene Ther. 1997; 4: 560-569Crossref PubMed Scopus (35) Google Scholar, 16Loubière L. Tiraby M. Cazaux C. Brisson E. Grisoni M. Zhao-Emonet J.C. Tiraby G. Klatzmann D. Gene Ther. 1999; 6: 1638-1642Crossref PubMed Scopus (22) Google Scholar). The human nucleoside kinases deoxycytidine kinase and deoxyguanosine kinase enhance sensitivity to cytotoxic nucleoside analogs and are also candidate genes for gene therapy (17Hapke D.M. Stegmann A.P.A. Mitchell B.S. Cancer Res. 1996; 56: 2343-2347PubMed Google Scholar, 18Manome Y. Wen P.Y. Dong Y. Tanaka T. Mitchell B.S. Kufe D.W. Fine H.A. Nat. Med. 1996; 2: 567-573Crossref PubMed Scopus (110) Google Scholar, 19Zhu C. Johansson M. Permert J. Karlsson A. J. Biol. Chem. 1998; 273: 14707-14711Abstract Full Text Full Text PDF PubMed Scopus (50) Google Scholar). Munch-Petersen and co-workers (20Munch-Petersen B. Piskur J. Sondergaard L. J. Biol. Chem. 1998; 273: 3926-3931Abstract Full Text Full Text PDF PubMed Scopus (89) Google Scholar) have purified a nucleoside kinase from Drosophila melanogaster that catalyzed the phosphorylation of all the natural pyrimidine and purine deoxyribonucleosides. In addition to its broad substrate specificity, the enzyme also exhibited a high catalytic rate that is 10–100-fold higher than reported for the previously studied nucleoside kinases. The broad substrate specificity of this enzyme, together with its high catalytic rate, makes it a unique member of the human and viral nucleoside kinase enzyme family. We have recently cloned the cDNA of this multisubstrate enzyme, named D. melanogasterdeoxyribonucleoside kinase (Dm-dNK), and shown that it also efficiently phosphorylates several anti-viral and anti-cancer nucleoside analogs (21Johansson M. Van Rompay A.R. Degrève B. Balzarini J. Karlsson A. J. Biol. Chem. 1999; 274: 23814-23819Abstract Full Text Full Text PDF PubMed Scopus (91) Google Scholar). In the present study, we decided to evaluate the possible use of Dm-dNK as a suicide gene by expressing the enzyme in human cancer cell lines. In summary, we have shown thatDm-dNK can be expressed in human cells with retained enzymatic activity and that it increases the sensitivity of the cells to several cytotoxic nucleoside analogs. We used a retrovirus vector based on the Moloney murine leukemia virus to generate a replication-deficient recombinant retrovirus containing the cDNA of Dm-dNK. Oligonucleotide primers containing engineered EcoRI and XhoI restriction enzyme sites were designed flanking the open reading frame ofDm-dNK cDNA (5′-AAGAATTCGGACTGATGGCGGAGGCAGCATCC and 5′-TTCTCGAGTGGTTATCTGGCGACCCTCTGGC). The primers were used in a polymerase chain reaction, and the DNA fragment was cloned into the EcoRI-XhoI site of the pLXSN plasmid vector (CLONTECH). The plasmid was purified using the NucleoBond plasmid purification kit (CLONTECH). The DNA sequence of the constructed plasmid was verified by DNA sequence determination using an ABI310 automated DNA sequencer (PerkinElmer Life Sciences). RetroPack PT67 packaging cells (CLONTECH) were cultured at 37 °C in Dulbecco's modified Eagle's medium supplemented with 10% (v/v) fetal calf serum (Life Technologies, Inc.), 100 units/ml penicillin, and 0.1 mg/ml streptomycin. The constructed pLXSN plasmid vector was transfected into the packaging cells using LipofectAMINE (Life Technology. Inc.) according to the protocol provided by the supplier. The medium from the transfected cells was collected 48 h after transfection, filtered through a 0.45-μm filter, and diluted 2-fold with fresh medium. The virus-containing medium was subsequently used to transduce the cancer cell lines as described below. TK-deficient osteosarcoma cells was a kind gift from Prof. J. Balzarini, Rega Institute, Leuven, Belgium. MIA PaCa-2 human pancreatic adenocarcinoma cells were purchased from the American Type Culture Collection. All cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% (v/v) fetal calf serum (Life Technologies, Inc.), 100 units/ml penicillin, and 0.1 mg/ml streptomycin. Cells were grown at 37 °C in a humidified incubator with a gas phase of 5% CO2. The cells lines were transduced with the retrovirus containing medium mixed with 4 μg/ml Polybrene. The cells were incubated for 48 h and then cultured continuously for 3 weeks in the presence of 1.0 mg/ml geneticin (Life Technologies, Inc.). Cell protein extracts were prepared as described (22Arnér E.S.J. Spasokoukotskaja T. Eriksson S. Biochem. Biophys. Res. Commun. 1992; 188: 712-718Crossref PubMed Scopus (146) Google Scholar). The assays were performed in 50 mmTris-HCl, pH 7.6, 5 mm MgCl2, 5 mmATP, 2 mm dithiothreitol, 15 mm NaF, 100 mm KCl, 0.5 mg/ml bovine serum albumin, and 0.6 μg of protein extract in a total volume of 35 μl. 2.5 μm[methyl-3H]dThd (Moravek Biochem), 3 μm[5-3H]-1-β-d-arabinofuranosylcytosine (araC) (Moravek Biochem), or 3 μm[8-3H]-2-chloro-2′-deoxyadenosine (CdA) (Moravek Biochem) were used in the assays and mixed with equivalent amounts of unlabeled substrates. The araC phosphorylation assay mixtures were supplemented with 50 μm tetrahydrouridine to inhibit deamination of araC by cytidine deaminase. Aliquots of the reaction mixture were spotted on Whatman DE-81 filters after 10-, 20-, and 30-min incubation at 37 °C. The filters were washed three times in 5 mmammonium formate. The nucleoside monophosphates were eluted from the filter with 0.5 m KCl, and the radioactivity was determined by scintillation counting. The cells were cultured on poly-l-lysine-coated chamber slides (Nunc, Inc.) for 24 h and subsequently labeled with [methyl-3H]dThd (Moravek Biochem) for 12 h. The slides were rinsed twice with phosphate-buffered saline, fixed 10 min in methanol:acetic acid (3:1), and washed three times with ice-cold 10% trichloroacetic acid, once with water, and once with methanol. The slides were coated with Hypercoat photoemulsion (Amersham Pharmacia Biotech) and exposed 1–3 weeks at 4 °C. The autoradiograms were developed using D-11 developer (Eastman Kodak Co.). We used the pEGFP-N1 plasmid vector (CLONTECH) to express theDm-dNK cDNA in fusion with the green fluorescent protein (dNK-GFP). Oligonucleotide primers containing engineeredEcoRI and SalI restriction enzyme sites were used to clone the open reading frame of Dm-dNK cDNA (5′-AAGAATTCGGACTGATGGCGGAGGCAGCATCC and 5′-ATGTCGACCTGGCGACCCTCTGGCGCTTGC) into theEcoRI-SalI site of the pEGFP-N1 vector. The C-terminal mutations (Δ247/dNK-GFP and Δ244–245/dNK-GFP) were introduced by using two extended 3′-oligonucleotide primers (5′-ATGTCGACCTGGCGACGCTCTGGCGCTTGCTGGGC and 5′-ATGTCGACCTGCGACCCTCTGGCTCTCGCTGGGCGACAC). The plasmids were transfected into the cell lines using LipofectAMINE (Life Technologies, Inc.) as described above. The nuclei of the cells were counterstained with 4′,6′-diamidino-2-phenylindole (DAPI). GFP and DAPI fluorescence was observed in a Nikon Eclipse E600 microscope equipped with a SPOT RT digital 1-β-d-arabinofuranosylthymine and were from was from (E)-5-(2-bromovinyl)-2′-deoxyuridine and were from Prof. J. Balzarini, Rega Institute, Leuven, Belgium. The cells were at in Nucleoside analogs were after 24 and the medium containing the nucleoside analogs was Cell was by a assay after 4 of was performed in The of the investigated compounds was as the of We used a retrovirus vector based on the Moloney murine leukemia virus to replication-deficient recombinant with and the Dm-dNK cDNA human osteosarcoma cell line and an MIA PaCa-2 human pancreatic adenocarcinoma cell line were transduced with the and of transfected cells were We used to in of into DNA of the thymidine kinase osteosarcoma cells The untransduced cells and the cells transduced with the pLXSN vector showed a the cells, phosphorylation of by thymidine kinase 2 and its subsequent into DNA J. Biol. Chem. Full Text PDF PubMed Google Scholar, J. Cell Biol. 1996; PubMed Scopus Google Scholar). In the cells expressingDm-dNK exhibited of the cell of into nuclear of the cells in nuclear that the of the transduced cancer cells expressed Dm-dNK. the total of nucleoside kinase activity in the cells, we determined the phosphorylation of and araC in cell protein extracts osteosarcoma cells in thymidine kinase activity showed of probably catalyzed by thymidine kinase 2 J. Biol. Chem. Full Text PDF PubMed Google Scholar). The cells transduced with the pLXSN retroviral vector showed of phosphorylation as the cells, the cells transfected with exhibited higher enzymatic activity than the cell MIA PaCa-2 cells exhibited a higher of activity with the osteosarcoma cells due to the retained of in the pancreatic the Dm-dNK increased the kinase activity in the MIA PaCa-2 cells as The phosphorylation of and araC in the cell protein extracts were also increased in the osteosarcoma and pancreatic adenocarcinoma cells with the cell lines and the cells transfected with pLXSN vector In summary, showed that human cancer cells transduced with the retroviral vector expressed Dm-dNK and that the in an of nucleoside and nucleoside analog We determined the sensitivity of the untransduced cells and the cells transduced with either the retroviral vector or the vector for several cytotoxic nucleoside analogs The was determined after 4 of as described The in sensitivity between the cell lines and the cells transduced with the pLXSN vector Dm-dNK was than for all investigated the osteosarcoma cells and the pancreatic cancer cells that expressed Dm-dNK showed an in sensitivity to several of the nucleoside analogs. The in sensitivity for the osteosarcoma cell was for and with a in with the untransduced araC and showed in and ganciclovir showed between and in with the untransduced was to either cell line at the investigated The in sensitivity for the MIA PaCa-2 cells was observed for with a increased and increased the sensitivity and showed a in sensitivity in cells, the sensitivity of and ganciclovir was by Dm-dNK in this cell of osteosarcoma and MIA PaCa-2 pancreatic adenocarcinoma cell lines to nucleoside in a In to the of the Dm-dNK in human cells, we constructed a fusion ofDm-dNK and GFP to the protein in The cells transfected with a plasmid encoding the fusion protein exhibited green fluorescence in the of the The nuclear was verified by the cells with on sequence Munch-Petersen and co-workers B. W. C. Sondergaard L. Piskur J. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar) two possible nuclear localization at and We decided to the of the nuclear localization signal in the of the protein in an using The nuclear localization signal was by either with a or by and with acid and acid expressed in the osteosarcoma cell and were retained in the and to the cell In summary, showed that the nuclear localization of Dm-dNK in human cells is by the C-terminal signal we have shown that the multisubstrate nucleoside kinase melanogaster its enzymatic activity expressed in human cells and that the activity results in an sensitivity to several cytotoxic pyrimidine and purine nucleoside analogs. These results suggest that Dm-dNK may be used as a suicide gene in combined gene/chemotherapy of cancer. of the most candidate nucleoside analogs to use in gene transfer are the pyrimidine analogs and is used in the treatment of several of tumors such as pancreatic adenocarcinoma and cell cancer J. J. 1997; PubMed Scopus Google Scholar). may be possible to the efficiency of this therapy by of cells in with theDm-dNK gene. the candidate nucleoside was developed as an and the been used to with varicella zoster J. De Clercq E. J. Cancer Full Text PDF PubMed Scopus Google Scholar). to untransduced cells, the cells expressingDm-dNK are to the The use of a nucleoside analog that is to Dm-dNK for such as and a nucleoside analog that shown in treatment of malignant such as is one possible to treatment for tumors with combined gene and the therapy with to may be to enhance the efficiency of nucleoside kinase suicide gene on HSV-1 cancer cells suggest that and may be ganciclovir with the D.S. Cancer Res. Google Scholar). of results in is for the of nucleoside analogs into a of the may also the phosphorylation of nucleoside analogs several nucleoside kinases are by The nucleoside analogs and are of once phosphorylated to their forms. Dm-dNK phosphorylates of it is possible that inhibit and enhance the phosphorylation of or nucleoside analogs that are by Dm-dNK. We are on to further the possible use of Dm-dNK as a suicide gene in to evaluate the possible of nucleoside analogs to this The unique of Dm-dNK as a suicide gene with HSV-1 TK and nucleoside kinases are its broad substrate specificity and high catalytic have in higher to the enzyme with purine (20Munch-Petersen B. Piskur J. Sondergaard L. J. Biol. Chem. 1998; 273: 3926-3931Abstract Full Text Full Text PDF PubMed Scopus (89) Google Scholar, M. Van Rompay A.R. Degrève B. Balzarini J. Karlsson A. J. Biol. Chem. 1999; 274: 23814-23819Abstract Full Text Full Text PDF PubMed Scopus (91) Google Scholar, B. W. C. Sondergaard L. Piskur J. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar). The in between purine and pyrimidine is also observed for nucleoside analogs. assays performed with recombinant Dm-dNK show that pyrimidine nucleoside analogs such as and efficiently with the natural pyrimidine and with most of the investigated purine nucleoside analogs such as and (21Johansson M. Van Rompay A.R. Degrève B. Balzarini J. Karlsson A. J. Biol. Chem. 1999; 274: 23814-23819Abstract Full Text Full Text PDF PubMed Scopus (91) Google Scholar). one of the is the purine nucleoside analog efficiently with and for phosphorylation by Dm-dNK. This also show a in in on HSV-1 cells suggest that the purine activity in may be increased by mutations that the enzymes to pyrimidine nucleoside analogs M.S. Sabo P. Adman E.T. Black M.E. Gene Ther. 1999; 6: 1415-1426Crossref PubMed Scopus Google Scholar). We are to a can be used to enhance purine nucleoside analog phosphorylation catalyzed Dm-dNK is sequence to the human nucleoside kinases deoxycytidine deoxyguanosine and thymidine kinase 2 (21Johansson M. Van Rompay A.R. Degrève B. Balzarini J. Karlsson A. J. Biol. Chem. 1999; 274: 23814-23819Abstract Full Text Full Text PDF PubMed Scopus (91) Google Scholar). The human enzymes in their by in either the or J. Biol. Chem. Full Text PDF PubMed Google Scholar, M. S. Karlsson A. Proc. Natl. Acad. Sci. U. S. A. 1997; PubMed Scopus Google Scholar, E.S.J. Med. Biol. Scopus Google Scholar, K. Johansson M. C. Karlsson A. 1999; PubMed Scopus Google Scholar). In the present we have shown that Dm-dNK is to the cell expressed in human cell lines. nuclear localization signal have been in theDm-dNK sequence B. W. C. Sondergaard L. Piskur J. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar). We showed that two mutants of the nuclear localization signal in the of the protein its nuclear These showed that this signal is the signal the nuclear We the nuclear of the enzyme is to the cells used in this or the enzyme is also in the of D. melanogaster cells as HSV-1 TK is also in the cell expressed in human cells B. Johansson M. De Clercq E. Karlsson A. Balzarini J. J. 1998; PubMed Google Scholar). The of the nuclear of nucleoside kinases suggest that phosphorylated nucleoside analogs may the nuclear and in nucleoside analogs sensitivity have been nucleoside analogs are phosphorylated in either of the two M. S. Karlsson A. Proc. Natl. Acad. Sci. U. S. A. 1997; PubMed Scopus Google Scholar). The of suicide gene therapy is on gene and the of the suicide gene in of the in on nucleoside kinase suicide gene therapy have been performed using or vector F.L. Wells J.M. J. Natl. Cancer Inst. 1990; 82: 297-300Crossref PubMed Scopus (500) Google Scholar, 3Culver K.W. Ram Z. Wallbridge S. Ishii H. Oldfield E.H. Blaese R.M. Science. 1992; 256: 1550-1552Crossref PubMed Scopus (1459) Google Scholar, 4Ram Z. Culver K.W. Oshiro E.M. Viola J.J. DeVroom H.L. Otto E. Long Z. Chiang Y. McGarrity G.J. Muul L.M. Katz D. Blaese R.M. Oldfield E.H. Nat. Med. 1997; 3: 1354-1361Crossref PubMed Scopus (641) Google Scholar, 5Klatzmann D. Valéry C.A. Bensimon G. Marro B. Boyer O. Mokhtari K. Diquet B. Salzmann J.-L. Philippon J. the Study Group on Gene Therapy for Glioblastoma Hum. Gene Ther. 1998; 9: 2595-2604Crossref PubMed Google Scholar). These show vector and in vector have been for viral and non-viral G. P. C. PubMed Scopus Google Scholar). also been in and of the suicide gene in have been shown to to a or cell These the for in that may be used for cells Cancer Gene Ther. 1998; Google the for gene in and cancer Cancer Res. Google and the protein for gene in tumors of J. T. J. T. M. Cancer Res. 1998; Google Scholar). of such as the G. S. J. M. L. T. H. H. Z. Gene Ther. 1999; 6: PubMed Scopus (50) Google Scholar) and the S. A. T. K. Y. T. Ishii K. Cancer Gene Ther. 1998; Google can also be used to in vector also for cells or of the cancer cells to vector or replication to cells G. P. C. PubMed Scopus Google Scholar). The recently developed the of in of human tumors for The in cells with A. C. S. M. L. A. A. Science. 1996; 274: PubMed Scopus Google and the virus cells in cells are killed by the virus. using the virus for treatment of tumors show results J. I. J. L. M. J. C. B. P. Nat. Med. 6: PubMed Scopus Google and it been that the may be further by the use of a suicide gene expressed by the virus J. I. J. L. M. J. C. B. P. Nat. Med. 6: PubMed Scopus Google Scholar, O. Blaese R.M. J.C. Cancer Res. 1999; Google Scholar). In the it be to evaluate and using the gene to the most killing of transduced cells as well as killing of untransduced via
39
An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells
James R. Bischoff, David H. Kirn, Angelica Williams et al. · Science · 1996 · 1.8K citations
Medicine, Cancer Biology, Oncology +14
Kenneth W. Culver, Zvi Ram, Stuart Wallbridge et al. · Science · 1992 · 1.5K citations
Medicine, Cancer Biology, Oncology +17
Fadlo R. Khuri, John Nemunaitis, Ian Ganly et al. · Nature Medicine · 2000 · 1.1K citations
Medicine, Oncology, Chemotherapy +8